Cancer treatment using targeted antibodies in vivo

FIELD: biotechnology.

SUBSTANCE: antibody binding to claudine 6 (CLDN6) and inhibiting tumor growth in vivo is claimed. The antibody can be used as part of a pharmaceutical composition, in a method for treatment of tumor related to cells expressing CLDN6. The invention also relates to hybridomas producing antibodies to CLDN6 deposited under the accession numbers DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), DSM ACC3057 (GT512muMAB 5F2D2).

EFFECT: invention effectively inhibits the growth of CLDN6-positive germ cell tumors, improves survival and prolongs life of patients with tumors.

17 cl, 18 dwg, 5 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to biochemistry, particularly to monoclonal antibodies binding to c-Met and able to inhibit both ligand-dependent, and ligand-independent c-Met activation. The above antibodies, as well as a composition containing them can be used for producing a therapeutic agent for treating cancer.

EFFECT: invention enables specifically inhibiting both ligand-dependent, and ligand-independent c-Met activation, particularly inhibiting c-Met dimerisation.

34 cl, 111 dwg, 4 tbl, 27 ex

FIELD: biotechnology.

SUBSTANCE: monoclonal antibody against human interleukin-6 is represented, which comprises hypervariable regions of the heavy chain CDRH-1: GFSLSTSGMGVG; CDRH-2: HIWWDDDKYYNPSLKS; and CDRH-3: RANYGTSYDYGMDY; and the hypervariable regions of the light chain CDRs CDRL-1: KASQSVSDVLT; CDRL-2: YASNRYT; and CDRL-3: QQGYRSPYT. In addition, the invention also relates to a hybridoma strain deposited in the Russian Collection of Cell Cultures under number RKKK(P) 751D, and producing the said antibody.

EFFECT: invention enables to expand the range of antibodies against human IL-6, having high ability to inhibit IL-6.

4 cl, 3 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology and medicine. What is presented is the mus musculus's hybrid culture cell strain α-producing monoclonal antibodies specific to human granulocyte colony-stimulating factor (GCSF) deposited in Special Cell Culture Collection of Institute of Cytology of the Russian Academy of Sciences, under No. PKKK ("П") 662 "Д".

EFFECT: invention enables extending the range of strains producing GCSF-specific monoclonal antibodies used for research and medical applications.

2 dwg, 2 tbl, 2 ex

FIELD: biotechnology.

SUBSTANCE: invention is a strain of cultured hybrid cells of animal Mus musculus L. CCHFV Vd-3 deposited in the State collection of pathogenic microorganisms and cell cultures "SCPM-OBOLENSK" under number H-27, which is a producer of monoclonal antibody 3H6/F2 to virus of Crimean Congo haemorrhagic fever (CCHF), is suitable for manufacture on its base of one of the components of a set of reagents for immunoenzymometric detection of antigens of CCHF virus in samples of biological material.

EFFECT: invention enables to obtain highly specific monoclonal antibodies suitable for use as one of the components of the set of reagents for immunoenzymometric detection of antigens of CCHF virus.

1 tbl, 3 ex

FIELD: biotechnology.

SUBSTANCE: invention is a strain of cultured hybrid cells of animal Mus musculus L. CCHFV Vd-2 deposited in the State collection of pathogenic microorganisms and cell cultures "SCPM-OBOLENSK" under number H-26, which is a producer of monoclonal antibody 1E2/E5 to virus of Crimean Congo haemorrhagic fever (CCHF), suitable for the manufacture on its base of one of the components of the set of reagents for immunoenzymometric detection of antigens of CCHF virus in samples of biological material.

EFFECT: invention enables to obtain highly specific monoclonal antibodies suitable for use as one of the components of the set of reagents for immunoenzymometric detection of antigens of CCHF virus.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses using the monoclonal antibodies (MCAs) produced by the hybridomas B/4H1 and 4H7 and directed to variable determinants as a part of influenza B virus proteins. The hybridoma B/4H1 and 4H7 strains are deposited in the Russian Collection of Vertebral Cell Cultures (RKKK P) under Nos. 719 D and 720 D, respectively. The two current influenza B viral evolution lines are identified with using the MCAs B/4H1 and MCAs 4H7 directed to variable determinants of Victorian-type and Yamagata-type influenza B hemagglutinin, respectively.

EFFECT: using the prepared MCA kit enables identifying the newly recovered influenza B viruses Besides, the MCAs under the invention may be used to study the antigenic structure and variability of this agent, to identify them as belonging to a specific evolution line; the MCAs may be also used to construct the diagnostic test systems.

3 cl, 12 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed is isolated monoclonal antibody, inducing cytotoxicity with respect to cancer cells, produced by hybridome, deposited in collection ID AC under number 051206-01, or its antigen-binding fragment. Described are: chimeric and hymanised versions, obtained from said antibody. Described is hybridome, producing monoclonal antibody and deposited in collection ID AC under number 051206-01, as well as composition based on said antibody for treatment of human cancer tumour.

EFFECT: application of invention ensures versions of monoclonal antibodies capable of inducing cytotoxicity in vitro in the absence of effector cells with respect to lung adenocarcenoma cells, which can be applied in tumour therapy.

5 cl, 5 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: hybrid cultured cell strain of the animals Mus museums 13F8 is produced by immunisation of Balb/c mice. The mice are immunised by four introductions of the recombinant antigen preparation F1 100 mcg/mouse. The third post-immunisation day is followed by splenocyte hybridisation of the immunised mice (1x108 cells) and mice myeloma cells P3-X63 Ag/8-653 (1×107cells). Polyethylene glycol (Sigma, the USA) is used as a fusion agent. The hybridisation is followed by hybridoma selection, screening, cloning and cryopreservation. Hybridoma is deposited in the State Collection of Pathogens and Cell Cultures of GKPM-Obolensk, No. N-18.

EFFECT: hybrid cultured cell strain producing monoclonal antibodies is applicable for constructing the based plague agent test systems.

7 dwg, 4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention presents cultivated hybrid cell strains of Mus. musculus animals Sp2/0-BC/rhPC-4F10, Sp2/0-BC/rhPC-1C6, Sp2/0-BC/rhPC-3H6, producers of monoclonal antibodies specific to human protein C. The strains are deposited in the Russian National Collection of Industrial Microorganisms of Federal Unitary Enterprise State Research Institute 'Genetics', No. (VKPM H-111), (VKPM H-112), respectively. The antibodies belong to hPROC-specific murine immunoglobulin G possessing cross-responsiveness, are selectively bound with human protein C and form a stable complex.

EFFECT: antibodies under the invention may be used for purposes of pharmaceutical and biomedical analytical studies, particularly for quantitative detection of the human recombinant factor C.

1 dwg, 4 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: there are presented versions of antibodies specific to claudin 18A2 produced by immunisation by a related amino acid sequence or a nucleic acid or a host cell expressing said peptide. The antibodies possess an ability to mediate elimination of cancer cells expressing claudin 18A2. There are disclosed versions of antibody-producing hybridomas. What is described is a conjugate or a pharmaceutical composition on the basis of antibodies or conjugates for elimination and/or inhibition of a cancer cell expressing claudin 18A2. There are disclosed versions of the method for growth inhibition and/or elimination of the cancer cell, as well as for treating or preventing a disease or a disorder involving cancer cells expressing claudin 18A2 with using the antibodies, conjugate and pharmaceutical composition under the invention.

EFFECT: use of the invention can find further application in medicine for treating cancer cells expressing claudin 18A2.

39 cl, 33 dwg, 5 tbl, 10 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to biotechnology and provides a α1,6-glucan-containing compound of Helicobacter pylori. The present invention also discloses a conjugate for inducing immune response against H.pylori, which contains said compound conjugated with a carrier protein. The present invention also discloses an immunogenic composition, use of said composition and a method of inducing immune response against H.pylori using said composition. The present invention also discloses immune serum for neutralising H.pylori in mammals, which is obtained by immunising said mammal with an immunogenic composition containing said immunogenic composition. The present invention discloses an antibody which recognises said α1,6-glucan-containing compound of H.pylori, use of said antibody and a method of inducing complement-mediated bacteriolysis of H.pylori strains which express α1,6-glucan using said antibody.

EFFECT: invention improves the effectiveness of immunogenic compositions against Hpylori.

27 cl, 8 dwg, 21 tbl, 11 ex

FIELD: biotechnologies.

SUBSTANCE: invention relates to compositions for intensive generation of a target protein in eucariotic cells, which includes a DNA vector with an insert of target protein gene and an agonist of cell receptors. Besides, the invention relates to methods for increasing generation of a target protein coded with a transgene in eucariotic cells by using the above compositions.

EFFECT: invention allows effective increase of generation of a target protein in eucariotic cells.

28 cl, 4 dwg, 7 tbl, 10 ex

FIELD: medicine

SUBSTANCE: what is presented is a trihybrid cell for protein expression, produced by hybridizing a first cell representing a stem cell or a cell originated from a virgin progenitor, a second cell originated from a common lymphoid progenitor, and a third cell originated from a common lymphoid progenitor, wherein the above first cell is other than a myeloma cell; a method for producing it and a method for producing proteins with using the same are also presented.

EFFECT: increasing protein stability produced by the above trihybrid cell and providing the more effective production of the therapeutic proteins ensure using the invention for protein expression applicable for diagnostic, preventive, therapeutic and/or scientific purposes.

64 cl, 62 dwg, 9 tbl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to molecular biology and cell technologies. Claimed is a method of obtaining a cell with the specified phenotype, where the said method includes stages of hybridisation of the first stem cell or the cell, derived from an uncommitted precursor cell, the second cell, derived from the common lymphoid precursor cell, and the third cell, derived from the common lymphoid precursor cell, with obtaining a hybrid cell, which demonstrates phenotypic plasticity, and influence on the said hybrid cell of conditions, selected from the group, consisting of the thymic stromal cell, cytokine, growth factor, immunoglobulin, ligand of receptors or their combination, in such a way that the said hybrid cell becomes the said cell with the phenotype of B-cell, T-cell, myeloid cell or dedifferentiated phenotype relative to the said hybrid cell.

EFFECT: due to the increase of functional stability of the hybrid cells and increase of their phenotypic plasticity and effectiveness of transdifferentiation, the invention can be used for tissue formation in medicine.

37 cl, 33 dwg, 11 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology and genetic engineering. A cell contains a construct, which comprises a sequence coding siRNA to a conserved region of a foot-and-mouth disease virus (FMDV) or avian influenza virus. What is disclosed is producing a transgenic vertebrate, other than a human from the above cells, which possess the resistance to the above viral diseases. The invention can be used in animal production and veterinary science.

EFFECT: what is presented is a transgenic embryo cell of a vertebrate, other than a human.

22 cl, 20 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology and biotechnology. There are presented versions of nucleic acids each of which codes a heavy-chain amino acid sequence of immunoglobulin IgG1. The above chain contains glycine-lysine dipeptide coded by ggaaaa, ggcaaa or gggaaa codon at the C terminal of the CH3 domain. There are described: a plasmid coding a heavy chain of immunoglobulin; version cells providing immunoglobulin IgG1 expression; a method for producing immunoglobulin in mammalian cells; a method for improving immunoglobulin expression in the mammalian cells; - using the versions of a nucleic acid.

EFFECT: using the invention provides preventing the by-product expression of weight 80 kDa that can find application in producing immunoglubulins.

18 cl, 7 dwg, 3 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry, particularly a polypeptide bearing a human BNP(1-32) epitope, for producing ligands that are directed against the human BNP(1-32) or human proBNP(1-108), where said polypeptide has the formula α1-R1-X1-FGRKMDR-X2-R22. Disclosed is use of said polypeptide to produce ligands directed against the human BNP(1-32) or human proBNP(1-108) and for producing a hybridoma which secretes a monoclonal antibody directed against the human BNP(1-32) or human proBNP(1-108). Disclosed is a method of producing a hybridoma which secretes a monoclonal antibody directed against the human BNP(1-32) or human proBNP(1-108), as well as the obtained hybridoma. Disclosed is a ligand which is specific to an epitope with the sequence FGRKMDR, as well as use thereof to detect human BNP(1-32) or human proBNP(1-108) in a biological sample. Disclosed are methods of detecting human BNP(1-32) or a human proBNP(1-108) derivative in a biological sample, a method for in vitro diagnosis, prediction, risk stratification or subsequent observation of long-term results of cardiac and/or vascular pathology in an individual, as well as a method for in vitro diagnosis of stroke in an individual using said ligand. Disclosed is a multi-epitope calibrator designed to obtain calibration curves for analysis of BNP(1-32), proBNP(1-108), as well as a kit for detecting human BNP(1-32) or human proBNP(1-108).

EFFECT: invention enables to efficiently detect cardiac and/or vascular pathologies in an individual.

15 cl, 17 dwg, 12 tbl, 18 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to immunology. What is presented is a lymphotoxin-alpha (LTα) antibody, including chimeric and humanised versions thereof. Where are disclosed compositions containing it, using it for preparing a medication for autoimmune disorders, a method of inhibiting ex vivo lymphotoxin-alpha activated cell proliferation with using the antibody under the invention, as well as a nucleic acid, an expression vector, a host cell and a method of producing the antibody that proceeds from using them.

EFFECT: present invention can find further application in a therapy of the autoimmune diseases.

51 cl, 21 ex, 27 dwg, 7 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and can be used to obtain monoclonal antibodies against the Yersinia pestis V antigen. The strain of hybrid animal cells Mus musculus 2B8 is obtained by immunising BALB/c mice. The mice are immunised by four-time administration of a recombinant V antigen in a dose of 100 mcg/mouse. On the third day after the last immunication, splenocytes of immune mice (1×108 cells) are hybridised with mouse myeloma cells RZ-X63 Ag/8-653 (1×107 cells). The fusion agent used is polyethylene glycol (Sigma, USA). Hybridisation is followed by selection, screening, cloning and cryopreservation of the hybridoma. The strain is deposited in the state collection of pathogenic microorganisms and cell cultures (GKPM-Obolensk) under number N-20.

EFFECT: strain of hybrid cultured cells, which produces monoclonal antibodies which are specific to the Y pestis V antigen, is suitable for constructing test systems for detecting plague pathogens.

8 dwg, 3 tbl, 7 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology and can be used to obtain monoclonal antibodies against the Yersinia pestis V antigen. The strain of hybrid animal cells Mus musculus 5G6 is obtained by immunising BALB/c mice. The mice are immunised by four-time administration of a recombinant V antigen in a dose of 100 mcg/mouse. On the third day after the last immunication, splenocytes of immune mice (1×108 cells) are hybridised with mouse myeloma cells RZ-X63 Ag/8-653 (1×107 cells). The fusion agent used is polyethylene glycol (Sigma, USA). Hybridisation is followed by selection, screening, cloning and cryopreservation of the hybridoma. The strain is deposited in the state collection of pathogenic microorganisms and cell cultures (GKPM-Obolensk) under number N-19.

EFFECT: strain of hybrid cultured cells, which produces monoclonal antibodies which are specific to the Y pestis V antigen, is suitable for constructing test systems for detecting plague pathogens.

8 dwg, 2 tbl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biochemistry. Described is antibody, which specifically binds with "receptor of advanced glycation endproducts" (RAGE). Claimed are: nucleic acid, which codes described antibody, composition for application as medication for treatment of disease or disorder, associated with RAGE. Also claimed is method of diagnosing RAGE-associated disease or disorder.

EFFECT: invention extends arsenal of means for treatment and diagnostics of RAGE-associated diseases.

12 cl, 5 dwg, 2 tbl, 5 ex

Up!